European Parliament

2014-2019



Plenary sitting

B8-0041/2017


5.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure on Marburg virus

Mireille D'Ornano

RE\1114321EN.docx PE596.751v01-00



B8-0041/2017

Motion for a European Parliament resolution on Marburg virus

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas Marburg virus, which was isolated in 1967 in Germany, is a virus belonging to the Filoviridae family which causes severe illness and leads to the death of infected persons in 25% to 80% of cases (Democratic Republic of Congo, 1998-2000);
- B. whereas Marburg virus is transmitted through contact with the blood of a contaminated person, but certain animals may carry the virus, particularly monkeys and bats and, according to some research, pigs;
- C. whereas no treatment exists for Marburg virus, but several research projects for the purpose of developing a vaccine are being carried out, particularly the project of the pharmaceutical company Johnson & Johnson whose Phase I clinical trials began on 12 September 2016;
- 1. Encourages the Commission to support current and future research projects to develop a vaccine against Marburg virus;
- 2. Alerts Member States to the dangers associated with imports of animals from regions where the disease is endemic.

